BETHESDA, MD – The US Food and Drug Administration is investigating a possible risk of heart failure among patients with type 2 diabetes treated with saxagliptin (Onglyza or Kombiglyze XR, ...
Saxagliptin, metformin HCl (ext-rel); 5mg/500mg, 5mg/1000mg, 2.5mg/1000mg; tabs. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing ...
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...
ORLANDO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate ...
The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit ...
The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is ...
Onglyza (saxagliptin) is a prescription drug used for type 2 diabetes. Onglyza can cause side effects that range from mild to serious. Examples include urinary tract infection (UTI) and headache.
The study also demonstrated that patients treated with ONGLYZA 5 mg plus metformin experienced a statistically significant weight decrease when compared to those treated with titrated glipizide plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results